ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Thursday, March 19, 2026

2:30PM-2:45PM
Abstract Number: 001
Longitudinal Cardiovascular Profiles of Youth with Childhood-onset Systemic Lupus Erythematosus
Plenary Abstract Session I
2:45PM-3:00PM
Abstract Number: 002
Assessing Juvenile Idiopathic Arthritis Healthcare Costs to Advance Value-Based Care
Plenary Abstract Session I
3:00PM-3:15PM
Abstract Number: 003
Dysregulated Macrophage–Fibroblast Crosstalk Identified by Single-Cell RNA-seq in Juvenile Systemic Scleroderma Skin
Plenary Abstract Session I
3:15PM-3:30PM
Abstract Number: 004
Barriers and Facilitators to Teratogenicity Knowledge and Application among Adolescents and Young Adults with Rheumatic Disease
Plenary Abstract Session I
5:11PM-5:16PM
Abstract Number: 018
Abnormal Cortical Grey Matter, White Matter and Subcortical Grey Matter Morphometry is Associated with Disease Features and Quality of Life in Patients with Craniofacial Localized Scleroderma
Abstracts: Imaging
5:11PM-5:16PM
Abstract Number: 021
Medication Changes and Lung Disease Activity in Systemic JIA: Six-Month Follow-Up of CARRA Registry SJIA-LD Cohort
Abstracts: Juvenile Idiopathic Arthritis
5:11PM-5:16PM
Abstract Number: 076
Understanding Etiology (CLUE) Study: Whole Genome Sequencing of Childhood-onset Systemic Lupus Erythematosus
Abstracts: Systemic Lupus Erythematosus
5:17PM-5:22PM
Abstract Number: 027
An Examination of Brain-age-related Deviations from Normative Neurodevelopmental Trajectory in Children with Childhood-Onset Systemic Lupus Erythematosus
Abstracts: Imaging
5:17PM-5:22PM
Abstract Number: 075
Association of Anti-Cytokine Biologics and JAK inhibitors with Bronchoalveolar Fluid Cytokine Profiles in Patients with Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD)
Abstracts: Juvenile Idiopathic Arthritis
5:17PM-5:22PM
Abstract Number: 010
Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)
Abstracts: Systemic Lupus Erythematosus
5:23PM-5:28PM
Abstract Number: 046
Antibiotic Exposure and New Diagnosis of Juvenile Idiopathic Arthritis: A Nested Case-Control Study in a Large US Population
Abstracts: Juvenile Idiopathic Arthritis
5:23PM-5:28PM
Abstract Number: 053
Association between Childhood Opportunity Index and Disparities in Health Care Access and Utilization in Childhood Onset Systemic Lupus Erythematosus
Abstracts: Systemic Lupus Erythematosus
5:23PM-5:28PM
Abstract Number: 030
Musculoskeletal and Nail Ultrasound Findings in Children with Psoriasis: A Case-Control Study
Abstracts: Imaging
5:29PM-5:34PM
Abstract Number: 017
High-Frequency Ultrasound Evaluation Predicts Disease Activity in Juvenile Localized Scleroderma
Abstracts: Imaging
5:29PM-5:34PM
Abstract Number: 077
Integrated Spatial Transcriptomics and Proteomics in Reveals Aberrant Lymphoid Networks in Pediatric Lupus Nephritis
Abstracts: Systemic Lupus Erythematosus
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology